Core Viewpoint - Beijing Wandong Medical Technology Co., Ltd. is utilizing idle raised funds and self-owned funds for cash management to enhance fund efficiency and increase returns for the company and its shareholders [3][9]. Summary by Sections Cash Management Purpose - The company aims to improve the efficiency of raised and self-owned funds while ensuring that the cash management does not affect the construction and use of raised funds or the safety of these funds [3]. Cash Management Amount - The total amount for this cash management is 0.7 billion yuan from raised funds and 1.46 billion yuan from self-owned funds [2][4]. Source of Funds and Related Information - The funds for this cash management come from idle raised funds and self-owned funds, which will not impact the implementation of fundraising projects. The company raised approximately 2.06 billion yuan through a non-public offering of shares [5]. Basic Situation of Cash Management - On April 18, 2025, the company used 0.7 billion yuan of raised funds to purchase structured deposits linked to gold prices. On April 29, 2025, it used 1 billion yuan of self-owned funds for a similar investment [6][7]. Review Procedures and Related Opinions - The cash management proposal was approved in meetings held on March 20, 2025, and April 16, 2025, with a maximum usage limit of 2 billion yuan for idle raised funds and 8 billion yuan for self-owned funds within a 12-month period [8]. Impact on the Company - The cash management is expected to enhance fund utilization efficiency and generate investment returns without affecting the company's normal operations or fundraising project plans [9]. Redemption Situation - Previous structured deposits have matured, yielding returns of 0.3989 million yuan, 0.1496 million yuan, and 0.1203 million yuan from various investments made by the company and its subsidiary [10][11]. Cash Management Quota Situation - As of the announcement date, the total cash management quota for raised funds is 2 billion yuan, with 1.2 billion yuan utilized, and for self-owned funds, it is 8 billion yuan, with 2.26 billion yuan utilized [11].

证券代码：600055 证券简称：万东医疗 编号：临 2025-019 北京万东医疗科技股份有限公司 关于公司及子公司使用闲置募集资金 及自有资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：募集资金 0.7 亿元、自有资金 1.46 亿元 履行的审议程序：2025年 3月 20日召开的第十届董事会第六次会议、 第十届监事会第六次会议及 2025 年 4 月 16 日召开的 2024 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金及自有资金进行现金管理的议 案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）及子公司为提 高募集资金和自有资金效率，合理利用部分闲置募集资金及自有资金，在 确保不影响募集资金项目建设和使用、募集资金和自有资金安全的情况下， 增加公司的收益，为公司及股东获取更多回报。 （二）现金管理金额 本次现金管理总金额为：公司使用募集资金 0.7 亿元,自有资金 1 亿元； 子公司 ...

Core Viewpoint - The company, Beijing Wandong Medical Technology Co., Ltd., has released its quarterly financial report for the first quarter of 2025, ensuring the accuracy and completeness of the information provided [1][2]. Financial Data Summary - The financial statements for the first quarter of 2025 have not been audited [3]. - The report includes major accounting data and financial indicators, although specific figures are not provided in the text [4]. - The company confirms that there are no significant changes in the major accounting data and financial indicators compared to the previous period [4]. Shareholder Information - The total number of ordinary shareholders and the situation of the top ten shareholders are mentioned, but specific details are not provided [4][5]. - There are no changes in the participation of major shareholders in the securities lending business [5]. Other Important Information - The company has not identified any other important information regarding its operational situation during the reporting period that needs to be highlighted to investors [5]. - The financial statements include the consolidated balance sheet, profit statement, and cash flow statement for the first quarter of 2025, all of which are unaudited [6].

据证券之星公开数据整理，近期万东医疗（600055）发布2025年一季报。截至本报告期末，公司营业总 收入3.73亿元，同比上升21.0%，归母净利润3505.22万元，同比上升5.4%。按单季度数据看，第一季度 营业总收入3.73亿元，同比上升21.0%，第一季度归母净利润3505.22万元，同比上升5.4%。本报告期万 东医疗应收账款上升，应收账款同比增幅达75.3%。 本次财报公布的各项数据指标表现一般。其中，毛利率37.75%，同比增0.77%，净利率9.35%，同比减 15.6%，销售费用、管理费用、财务费用总计6854.93万元，三费占营收比18.36%，同比增15.8%，每股 净资产6.83元，同比增1.22%，每股经营性现金流-0.3元，同比减176.24%，每股收益0.05元，同比增 6.38% | 项目 | 2024年一季报 | 2025年一季报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 3.08亿 | 3.73亿 | 21.00% | | 归母净利润(元) | 3325.74万 | 3505.22万 | 5.40% | | 扣非净利润 ...

Group 1 - The stock price of Wandong Medical (600055) closed at 17.58 yuan on April 25, 2025, up 2.57% from the previous week [1] - The company's total market capitalization is 12.36 billion yuan, ranking 19th out of 124 in the medical device sector and 1244th out of 5149 in the A-share market [1] Group 2 - As of March 31, 2025, the number of shareholders for Wandong Medical was 30,400, an increase of 397 from February 28, representing a growth rate of 1.32% [2][3] - The average number of shares held per shareholder decreased from 23,400 to 23,100, with an average holding value of 385,300 yuan [2] - The company's Q1 2025 report shows a main revenue of 373 million yuan, a year-on-year increase of 21.0% [2][3] - The net profit attributable to the parent company was 35.05 million yuan, up 5.4% year-on-year, while the net profit excluding non-recurring items decreased by 25.77% to 23.27 million yuan [2] - The company's debt ratio stands at 8.98%, with investment income of -48,800 yuan and financial expenses of -13.87 million yuan, while the gross profit margin is 37.75% [2]

Financial Performance - The company's operating revenue for Q1 2025 was approximately CNY 373.28 million, representing a 21.00% increase compared to CNY 308.50 million in the same period last year[3]. - The net profit attributable to shareholders was CNY 35.05 million, a 5.40% increase from CNY 33.26 million year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 25.77% to CNY 23.27 million from CNY 31.35 million in the previous year[3]. - The company reported a net profit of CNY 1,093,370,979.96 for the period, compared to CNY 1,058,318,801.32 previously, indicating an increase of 3.31%[17]. - Total operating revenue for Q1 2025 reached ¥373,277,998.39, a 20.9% increase from ¥308,495,149.50 in Q1 2024[19]. - Net profit for Q1 2025 was ¥34,897,655.15, slightly up from ¥34,172,999.88 in Q1 2024, representing a 2.1% increase[21]. - The total comprehensive income for Q1 2025 was ¥34,897,655.15, compared to ¥34,172,999.88 in Q1 2024, indicating a 2.1% increase[21]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -208.67 million, a significant decline of 176.24% compared to CNY -75.54 million in the same period last year[3]. - Cash flow from operating activities showed a net outflow of ¥208,666,546.23 in Q1 2025, worsening from a net outflow of ¥75,537,833.74 in Q1 2024[22]. - Cash and cash equivalents at the end of Q1 2025 were ¥1,416,153,004.04, down from ¥3,015,710,522.47 at the end of Q1 2024[24]. - The company's cash and cash equivalents decreased to CNY 2,998,739,914.09 from CNY 3,586,378,532.07, representing a decline of 16.36%[15]. - The company experienced a net cash outflow from investing activities of ¥378,152,876.54 in Q1 2025, compared to a net outflow of ¥322,406,925.94 in Q1 2024[23]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5.40 billion, down 1.34% from CNY 5.47 billion at the end of the previous year[4]. - As of March 31, 2025, the total current assets of Beijing Wandong Medical Technology Co., Ltd. amounted to CNY 4,373,977,612.33, a decrease of 1.73% from CNY 4,451,370,073.15 on December 31, 2024[15]. - The total liabilities decreased to CNY 484,497,805.50 from CNY 592,503,982.96, a reduction of 18.2%[17]. - The total equity attributable to shareholders increased to CNY 4,802,598,757.68 from CNY 4,767,546,579.04, reflecting a growth of 0.73%[17]. - The company's total assets amounted to CNY 5,396,997,270.47, down from CNY 5,470,493,043.29, a decrease of 1.34%[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,385, with the largest shareholder being Midea Group Co., Ltd., holding 45.46% of the shares[12]. - The company has not reported any significant changes in shareholder relationships or actions related to financing or securities lending[14]. Expenses - Total operating costs for Q1 2025 were ¥358,486,933.72, up 29.0% from ¥277,816,152.47 in Q1 2024[19]. - Research and development expenses increased to ¥55,667,880.17 in Q1 2025, a 58.5% rise compared to ¥35,189,394.52 in Q1 2024[19]. - The company reported a significant increase in sales expenses, which rose to ¥60,600,749.81 in Q1 2025 from ¥49,631,679.54 in Q1 2024, marking a 21.5% increase[19]. Other Financial Metrics - The weighted average return on equity increased by 0.03 percentage points to 0.73% from 0.70% year-over-year[3]. - The company recognized government subsidies amounting to CNY 12.46 million, which are closely related to its normal business operations[6]. - The company experienced a 100.00% increase in trading financial assets due to the use of idle funds to purchase financial products[10]. - The company reported a significant increase of 463.02% in prepayments, primarily due to product structure adjustments and production preparations[10]. - The company's inventory decreased to CNY 197,782,413.16 from CNY 214,942,655.77, a decline of 7.99%[16]. - The non-current assets totaled CNY 1,023,019,658.14, slightly up from CNY 1,019,122,970.14[16]. - Accounts receivable increased to CNY 470,738,186.80, up 23.5% from CNY 381,205,179.51[15].

Core Viewpoint - The company, a leading domestic medical imaging equipment manufacturer, has undergone significant strategic empowerment since Midea Group's acquisition in 2021, focusing on product structure upgrades and marketing reforms to enhance its market position and operational resilience [1][2]. Group 1: Company Performance - In 2024, the company achieved a revenue of 1.524 billion yuan (+23.26%) and a net profit of 157 million yuan (-16.54%), indicating a resilient performance despite industry pressures [1]. - The company has implemented a new round of equity incentive plans in March 2025, emphasizing revenue growth and R&D investment, reflecting confidence in its development [1]. Group 2: Market Position and Product Development - The company remains the domestic leader in the DR segment, with a continuous increase in market share and a focus on high-end imaging equipment such as MR, CT, and DSA [2]. - The introduction of innovative products, including the world's first full-field DR high-end product and a 1.5T superconducting MR, has strengthened the company's competitive position, particularly in secondary and lower-tier medical institutions [2]. Group 3: AI Integration and Future Growth - The AI medical imaging market is projected to reach 8.84 billion yuan in 2024, with a CAGR of nearly 50% until 2028, prompting the company to strategically partner with Alibaba Health to enhance its AI capabilities [3]. - The company's AI initiatives, including the Kunlun AI smart imaging platform and the rapid development of its imaging SaaS platform, have led to significant growth in service coverage, reaching over 7,000 hospitals and serving more than 60 million patients [3]. - Revenue from the company's cloud business, Wanliyun, has grown from 66 million yuan in 2020 to 124 million yuan in 2023, with a CAGR of 23.2%, indicating robust growth potential as AI business matures [3].

证券代码：600055 证券简称：万东医疗 公告编号：临 2025-018 北京万东医疗科技股份有限公司关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 4 月 28 日（星期一）14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 4 月 21 日（星期一）至 4 月 25 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wdm_ir@wandong.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 北京万东医疗科技股份有限公司（以下简称"公司"）已于 2025 年 3 月 22 日发布公司 2024 年度报告，并拟于 2025 年 4 月 26 日发布公司 2025 ...

北京市嘉源律师事务所 关于北京万东医疗科技股份有限公司 2024 年年度股东大会的法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 R EUME S Fi YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI 深圳 SHENZHEN · 香港 HONGKONG · 广州 GUANGZHOU · 西安 XI AN 致:北京万东医疗科技股份有限公司 在本法律意见书中,本所律师仅对本次股东大会的召集、召开程序、出席会 议人员资格、召集人资格、会议表决程序、表决结果等所涉及的有关法律问题发 表意见,不对本次股东大会审议的议案内容以及该等议案所表述的事实或数据的 真实性及准确性发表意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信用原则, 进行了充分的核查验证,保证本法律意见所认定的事实真实、准确、完整,所发 北京市嘉源律师事务所 关于北京万东医疗科技股份有限公司 2024 年年度股东大会的法律意见书 嘉源 ...

证券代码：600055 证券简称：万东医疗 公告编号：2025-016 北京万东医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 4 月 16 日 (二) 股东大会召开的地点：公司本部（北京市朝阳区酒仙桥东路 9 号 院 3 号楼） (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份 情况： | 1、出席会议的股东和代理人人数 | 213 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 326,828,263 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | | | 总数的比例（%） | 46.4864 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持 情况等。 会议由公司董事长胡自强先生主持，采取现场及网络相结合的方式投票 表决并形成会议决议，会议的召集、召开及表决符合《 ...